Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma

@inproceedings{Hsu2017ClinicalAP,
  title={Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma},
  author={Chiun Yu Hsu and Ann-Lii Cheng},
  year={2017}
}
The antitumor mechanisms of sorafenib in hepatocellular carcinoma (HCC) may involve complex interactions of signaling pathways in cancer cells and the tumor microenvironment, thus rendering the exploration of strategies to reverse sorafenib resistance an extremely challenging task. This chapter reviews the results of clinical trials of systemic therapy for patients with sorafenib-resistant HCC and preclinical studies exploring mechanisms and biomarkers of sorafenib resistance in HCC. The… CONTINUE READING

Topics from this paper.